| Title |
A Revisited Strategy for Antiepileptic Drug Development in Children
|
|---|---|
| Published in |
CNS Drugs, January 2013
|
| DOI | 10.1007/s40263-012-0035-9 |
| Pubmed ID | |
| Authors |
Catherine Chiron, Behrouz Kassai, Olivier Dulac, Gerard Pons, Rima Nabbout |
| Abstract |
Randomized controlled trials (RCTs) in refractory paediatric epilepsy usually involve the two main types of epilepsy shared by children and adults, focal epilepsy and Lennox-Gastaut syndrome (LGS). Most other epilepsy syndromes, specifically paediatric, are excluded from drug development. In order to identify among them the candidate(s) for dedicated RCTs with a new drug, the European Medicine Agency (EMA) recently recommended proceeding in two steps: (1) an exploratory (prospective-observational) trial (POT) including a large variety of paediatric epilepsy syndromes and (2) a subsequent RCT in each of those that disclose a signal for possible efficacy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| United States | 1 | 2% |
| Unknown | 40 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 21% |
| Student > Bachelor | 5 | 12% |
| Student > Postgraduate | 4 | 10% |
| Other | 3 | 7% |
| Professor > Associate Professor | 3 | 7% |
| Other | 8 | 19% |
| Unknown | 10 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 33% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 10% |
| Agricultural and Biological Sciences | 4 | 10% |
| Psychology | 2 | 5% |
| Neuroscience | 2 | 5% |
| Other | 5 | 12% |
| Unknown | 11 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 January 2013.
All research outputs
#18,327,422
of 22,694,633 outputs
Outputs from CNS Drugs
#1,163
of 1,304 outputs
Outputs of similar age
#217,403
of 280,564 outputs
Outputs of similar age from CNS Drugs
#10
of 10 outputs
Altmetric has tracked 22,694,633 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,304 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.1. This one is in the 6th percentile – i.e., 6% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,564 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one.